SEC-sourced researchBeta
LCTX
Lineage Cell Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0000876343
- Exchange
- NYSE
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Mar 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 9,499,000.0000 | Mar 5, 2026 |
| December 2025 | 14,556,000.0000 | Mar 5, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 14,556,000.0000 | -63,533,000.0000 | -18,919,000.0000 | 112,584,000.0000 | 69,238,000.0000 | Mar 5, 2026 |
| December 2024 | 9,499,000.0000 | -18,609,000.0000 | -23,092,000.0000 | 113,218,000.0000 | 36,206,000.0000 | Mar 5, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $14.56M | December 2025 | Mar 5, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $9.5M | December 2024 | Mar 5, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$63.53M | December 2025 | Mar 5, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$18.92M | December 2025 | Mar 5, 2026 | 10-K |
| Total assetsAssets | $112.58M | December 2025 | Mar 5, 2026 | 10-K |
| Total liabilitiesLiabilities | $69.24M | December 2025 | Mar 5, 2026 | 10-K |